Anavex Life Sciences Corp (AVXL)

[Doc328]

Agree with TTT. Also, when additional data from the rivastigmine phase 3 study with 500 patients was evaluated, the CDR-COA test (primary endpoint) was significant at 16 weeks. If PDD data is good, I would expect the phase 3 to be 24-26 weeks, like the rivastigmine study.